NanoKTN Sparks New Nanomedicine Intelligence Start-Up: NanoScientium
28/02/2014 Innovate UK
The Nanotechnology Knowledge Transfer Network (NanoKTN - www.nanoktn.com), one of the UK's primary knowledge-based networks for Micro and Nanotechnologies, is pleased to announce the foundation of a new start-up company, NanoScientium, resulting from a NanoKTN NanoPharm focus group meeting held last year at the Stevenage Bioscience Catalyst (SBC).The NanoKTN NanoPharm focus group meeting - Adoption of Nanotechnology Pharma: Pathways to Commercialise Nanomedicines - was held in February 2013 and brought together relevant pharma industry experts, regulators and academics, to scope out a plan that would serve to catalyse an increase in the number of nanomedicine projects in the UK.
Dr Felicity Sartain, Founder and Director of NanoScientium, comments "One of the key aspects that arose from the meeting was that there is a lot of information and data openly available in this space, thus significant value would be brought to this community if this information could be harnessed and translated to specific company needs. Consequently, with support provided by both Stevenage Bioscience Catalyst and the NanoKTN, we set up NanoScientium to provide comprehensive analysis of technical, clinical and market information for those investing capital or resources into nanomedicines, nanosimilars or medical devices."
Martino Picardo, CEO of Stevenage Bioscience Catalyst, said "Both SBC and NanoScientium share a common interest and ambition to explore opportunities in the big data and convergent medical technologies area; we see each other as excellent partners."
NanoScientium provides evidence based assessments of nanotechnologies to determine their potential as nanomedicines. By doing this, NanoScientium enables route to market strategies, including clinical and regulatory pathways, illustrates technology or company positions in the competitive landscape, and values their markets.
Dr Alec Reader, Director at the NanoKTN, added, "The global nanomedicine market is anticipated to grow to $130.9 billion by 2016 and we believe that NanoScientium's provision of evidence-based assessments of nanomedicines by senior experts in the field, will positively impact the way that investors, and the public in general, look at these new disruptive technologies. We look forward to seeing the future success of NanoScientium and are delighted to have played a part in its foundation."
For more information, please visit: www.nanoscientium.com
Print this article
Process and Control Today are not responsible for the content of submitted or externally produced articles and images. Click here to email us about any errors or omissions contained within this article.